Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics

ConditionsCoronary Artery Disease Arrhythmias, Cardiac Heart Valve Diseases Aortic Dissection Heart Neoplasms Myocarditis Hypertension Cardiomyopathies Structural Heart Disease Ischemic Cerebrovascular Disease Hemorrhagic Cerebrovascular Disease Brain Neoplasms

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age3-80

SponsorFirst Affiliated Hospital Xi'an Jiaotong University

About this trial

The etiology and specific pathogenesis of many cardiovascular diseases such as coronary atherosclerosis, cardiomyopathy, atrial fibrillation, and stroke are still unclear. Improving diagnosis and treatment, clarifying the pathogenesis, and providing scientific basis for the prevention and treatment are hot research topics in the study of cardiovascular and cerebrovascular diseases. This study intends to collect clinical data and biological specimen data of patients with cardiovascular and cerebrovascular diseases who meet the inclusion and exclusion criteria, and use multi-omics technology to deeply understand the pathogenic mechanisms of cardiovascular and cerebrovascular diseases and provide new ideas for specific and individualized treatment of patients with cardiovascular and cerebrovascular diseases, to construct early predictive prognostic models and provide a basis for effective treatment of clinical practice in patients with cardiovascular and cerebrovascular diseases.

Eligibility criteria

Qualifiers

Patients who are regularly visited and followed up in the appropriate patient; department.

coronary artery disease group;

arrhythmia group;

heart valve disease group;

Disqualifiers

Age <3 years or >80 years old;

Pregnant and lactating women;

The patient declined to provide informed consent to participate in the study;

None of the above was met, but the patient was temporarily unable to sign the informed consent form due to coma and other reasons, and no legal representative signed it instead. Depending on the patient's condition, the patient may not be able to regain consciousness and sign the informed consent form.

Trial design

Treatments tested in this trial

Observational; No Interventions were given.

Treatment groups

25,000 Participants

are divided into 12 treatment groups

Treatment groups

See each treatment group below.

Sponsors and collaborators

First Affiliated Hospital Xi'an Jiaotong University

Lead sponsor

Xi'an Gaoxin Hospital

Collaborator

First Affiliated Hospital of Chongqing Medical University

Collaborator

General Hospital of Ningxia Medical University

Collaborator

Second Affiliated Hospital of Nanchang University

Collaborator

Source ClinicalTrials.gov